(NASDAQ: CDXS) Codexis's forecast annual revenue growth rate of 20.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Codexis's revenue in 2025 is $52,932,000.On average, 9 Wall Street analysts forecast CDXS's revenue for 2025 to be $6,198,510,783, with the lowest CDXS revenue forecast at $5,629,738,144, and the highest CDXS revenue forecast at $7,207,885,763. On average, 8 Wall Street analysts forecast CDXS's revenue for 2026 to be $6,522,955,967, with the lowest CDXS revenue forecast at $4,762,262,769, and the highest CDXS revenue forecast at $7,844,311,366.
In 2027, CDXS is forecast to generate $8,756,948,932 in revenue, with the lowest revenue forecast at $8,019,540,669 and the highest revenue forecast at $9,437,091,536.